Acumen Pharmaceuticals (NASDAQ: ABOS) officer files Rule 10b5-1 tax sales

Q: What insider transaction did Acumen Pharmaceuticals (ABOS) report for James J. Doherty?

The report shows that James J. Doherty , President and CDO of Acumen Pharmaceuticals, Inc. , sold shares of common stock in two transactions on January 7 and 8, 2026 , and held 54,033 shares directly after the second transaction.

Q: How many Acumen Pharmaceuticals (ABOS) shares were sold and at what prices?

Doherty sold 1,700 shares of Acumen common stock at a weighted average price of $1.9879 on January 7, 2026 , and 6,467 shares at a weighted average price of $1.8198 on January 8, 2026 .

Q: How many Acumen Pharmaceuticals (ABOS) shares does James J. Doherty own after these transactions?

After the reported sales, the Form 4 states that James J. Doherty beneficially owns 54,033 shares of Acumen Pharmaceuticals common stock directly.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Acumen Pharmaceuticals officer James J. Doherty reported automatic sales of company stock to cover taxes tied to restricted stock unit vesting. On January 7, 2026, he sold 1,700 shares of common stock at a weighted average price of $1.9879, and on January 8, 2026 he sold 6,467 shares at a weighted average price of $1.8198, in each case through a Rule 10b5-1 trading plan.

The filing states that these were “sell to cover” transactions to satisfy tax withholding obligations and that Doherty held 54,033 shares of common stock directly after the second sale. It also notes that the reported beneficial ownership reflects a correction of a typographical error in a prior Form 4 that had overreported an RSU grant to Doherty by 400 shares.

Insider Trade Summary

Net Seller: 8,167 shares ($15,148)

Net Sell 2 txns

Insider Doherty James J.

Role President and CDO

Sold 8,167 shs ($15K)

Type	Security	Shares	Price	Value
Sale	Common Stock	6,467	$1.8198	$12K
Sale	Common Stock	1,700	$1.9879	$3K

Holdings After Transaction: Common Stock — 54,033 shares (Direct)

Footnotes (1)

Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9550 to $2.0200. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Number of securities reported as beneficially owned by Mr. Doherty following the reported transaction reflects the correction of a typographical error in the Form 4 report filed January 7, 2025, which overreported the number of RSUs granted to Mr. Doherty on January 6, 2025, by 400 shares. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7200 to $1.9500. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Form 4 Insider Transactions: What Each Field Means →

01/09/2026 - 04:39 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doherty James J.

(Last)

(First)

(Middle)

C/O ACUMEN PHARMACEUTICALS, INC.

1210-1220 WASHINGTON STREET, SUITE 210

(Street)

NEWTON

02465

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Acumen Pharmaceuticals, Inc. [ ABOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CDO

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/07/2026		S		1,700⁽¹⁾	D	$1.9879⁽²⁾	60,500⁽³⁾	D
Common Stock	01/08/2026		S		6,467⁽¹⁾	D	$1.8198⁽⁴⁾	54,033	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025.

2. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9550 to $2.0200. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. Number of securities reported as beneficially owned by Mr. Doherty following the reported transaction reflects the correction of a typographical error in the Form 4 report filed January 7, 2025, which overreported the number of RSUs granted to Mr. Doherty on January 6, 2025, by 400 shares.

4. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7200 to $1.9500. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Derek Meisner, Attorney-in-Fact	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Acumen Pharmaceuticals (ABOS) report for James J. Doherty?

The report shows that James J. Doherty, President and CDO of Acumen Pharmaceuticals, Inc., sold shares of common stock in two transactions on January 7 and 8, 2026, and held 54,033 shares directly after the second transaction.

How many Acumen Pharmaceuticals (ABOS) shares were sold and at what prices?

Doherty sold 1,700 shares of Acumen common stock at a weighted average price of $1.9879 on January 7, 2026, and 6,467 shares at a weighted average price of $1.8198 on January 8, 2026.

Why did the Acumen Pharmaceuticals (ABOS) officer sell shares in this Form 4 filing?

The filing explains that the shares were sold through an automatic “sell to cover” transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units under a Rule 10b5-1 trading plan adopted on September 30, 2025.

How many Acumen Pharmaceuticals (ABOS) shares does James J. Doherty own after these transactions?

After the reported sales, the Form 4 states that James J. Doherty beneficially owns 54,033 shares of Acumen Pharmaceuticals common stock directly.

Did the Acumen Pharmaceuticals (ABOS) Form 4 include any corrections to prior reports?

Yes. A footnote states that the number of securities reported as beneficially owned reflects the correction of a typographical error in a Form 4 filed on January 7, 2025, which had overreported an RSU grant to Doherty by 400 shares.

Was the Acumen Pharmaceuticals (ABOS) insider sale under a Rule 10b5-1 trading plan?

According to the filing, the “sell to cover” transactions were executed pursuant to a Rule 10b5-1 trading plan that the reporting person adopted on September 30, 2025.